Age-specific HPV prevalence among 116,052 women in Australia’s renewed cervical screening program: A new tool for monitoring vaccine impact
•HPV based cervical screening can generate precise HPV prevalence estimates.•Among 116,118 samples from Australian women aged 25–74, 9.2% had oncogenic HPV.•HPV16/18 was stable with age, unlike other oncogenic types, due to HPV vaccination. Australia’s transition to primary human papillomavirus (HPV...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2019-01, Vol.37 (3), p.412-416 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 416 |
|---|---|
| container_issue | 3 |
| container_start_page | 412 |
| container_title | Vaccine |
| container_volume | 37 |
| creator | Brotherton, Julia ML Hawkes, David Sultana, Farhana Malloy, Michael J. Machalek, Dorothy A. Smith, Megan A. Garland, Suzanne M. Saville, Marion |
| description | •HPV based cervical screening can generate precise HPV prevalence estimates.•Among 116,118 samples from Australian women aged 25–74, 9.2% had oncogenic HPV.•HPV16/18 was stable with age, unlike other oncogenic types, due to HPV vaccination.
Australia’s transition to primary human papillomavirus (HPV) based cervical screening, has for the first time, provided a passive mechanism for monitoring the impact of vaccination on infection prevalence among women attending screening. We assessed oncogenic HPV prevalence by single year of age in the first 7 months of the program, using data collected from a large screening laboratory in Victoria, Australia, which is routinely screening using cobas 4800, cobas 6800 and Seegene assays. Among 116,052 primary screening samples from women aged 25–74, 9.25% (95%CI: 9.09–9.42%) had oncogenic HPV detected: 2.14% (95%CI: 2.05–2.22%) were 16/18 positive and 7.12% (95%CI: 6.97–7.27%) were positive for only non-16/18 HPV. Prevalence peaked at age 25–29 then decreased with age, but this was driven by non-16/18 types. HPV16/18 prevalence remained low and flat across ages, contrasting with pre-vaccination epidemiology when HPV16/18 peaked in young women. HPV-based screening can precisely monitor HPV prevalence. |
| doi_str_mv | 10.1016/j.vaccine.2018.11.075 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2157668714</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X18316384</els_id><sourcerecordid>2157668714</sourcerecordid><originalsourceid>FETCH-LOGICAL-c393t-8060b4bdcc7b5170be931f63c50ce0bc1e7291b623c4fd1cce437f8e7fc91fdd3</originalsourceid><addsrcrecordid>eNqFkbGO1DAQhi0E4paDRwBZoqEgwRPHcUKDVifgkE6CAhCd5UwmK6-SONjJnuh4AR6A1-NJ8GoXChoqN9__e2Y-xh6DyEFA9WKfHyyimygvBNQ5QC60usM2UGuZFQrqu2wjiqrMShBfLtiDGPdCCCWhuc8upFAKmlpv2I_tjrI4E7reIb_-8JnPgQ52oAmJ29FPOw5QPReq4Ld-pIm7iW_XuAQ7OPvr-8_IA010Sx1HCgeHduARA9HkUnIOfhfs-JJveWL44v3Aex94qnWLD0fkvAR342xxecju9XaI9Oj8XrJPb15_vLrObt6_fXe1vclQNnLJalGJtmw7RN0q0KKlRkJfSVQCSbQIpIsG2qqQWPYdIFIpdV-T7rGBvuvkJXt26k0Tfl0pLmZ0EWkY7ER-jaYApauq1lAm9Ok_6N6vYUrTJaoqtAQpmkSpE4XBxxioN3Nwow3fDAhz9GX25ryqOfoyACb5Srkn5_a1Han7m_ojKAGvTgClcxwcBRPRHeV0LhAupvPuP1_8BmBYqvI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2162731309</pqid></control><display><type>article</type><title>Age-specific HPV prevalence among 116,052 women in Australia’s renewed cervical screening program: A new tool for monitoring vaccine impact</title><source>Elsevier ScienceDirect Journals Complete</source><creator>Brotherton, Julia ML ; Hawkes, David ; Sultana, Farhana ; Malloy, Michael J. ; Machalek, Dorothy A. ; Smith, Megan A. ; Garland, Suzanne M. ; Saville, Marion</creator><creatorcontrib>Brotherton, Julia ML ; Hawkes, David ; Sultana, Farhana ; Malloy, Michael J. ; Machalek, Dorothy A. ; Smith, Megan A. ; Garland, Suzanne M. ; Saville, Marion</creatorcontrib><description>•HPV based cervical screening can generate precise HPV prevalence estimates.•Among 116,118 samples from Australian women aged 25–74, 9.2% had oncogenic HPV.•HPV16/18 was stable with age, unlike other oncogenic types, due to HPV vaccination.
Australia’s transition to primary human papillomavirus (HPV) based cervical screening, has for the first time, provided a passive mechanism for monitoring the impact of vaccination on infection prevalence among women attending screening. We assessed oncogenic HPV prevalence by single year of age in the first 7 months of the program, using data collected from a large screening laboratory in Victoria, Australia, which is routinely screening using cobas 4800, cobas 6800 and Seegene assays. Among 116,052 primary screening samples from women aged 25–74, 9.25% (95%CI: 9.09–9.42%) had oncogenic HPV detected: 2.14% (95%CI: 2.05–2.22%) were 16/18 positive and 7.12% (95%CI: 6.97–7.27%) were positive for only non-16/18 HPV. Prevalence peaked at age 25–29 then decreased with age, but this was driven by non-16/18 types. HPV16/18 prevalence remained low and flat across ages, contrasting with pre-vaccination epidemiology when HPV16/18 peaked in young women. HPV-based screening can precisely monitor HPV prevalence.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2018.11.075</identifier><identifier>PMID: 30551987</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Age ; Australia ; Cellular biology ; Cervical cancer ; Cervical screening ; Confidence intervals ; Epidemiology ; Human papillomavirus ; Infections ; Laboratories ; Medical screening ; Monitoring ; Pathology ; Prevalence ; Sexual behavior ; Surveillance ; Vaccination ; Vaccines ; Womens health</subject><ispartof>Vaccine, 2019-01, Vol.37 (3), p.412-416</ispartof><rights>2018 Elsevier Ltd</rights><rights>Copyright © 2018 Elsevier Ltd. All rights reserved.</rights><rights>2018. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c393t-8060b4bdcc7b5170be931f63c50ce0bc1e7291b623c4fd1cce437f8e7fc91fdd3</citedby><cites>FETCH-LOGICAL-c393t-8060b4bdcc7b5170be931f63c50ce0bc1e7291b623c4fd1cce437f8e7fc91fdd3</cites><orcidid>0000-0002-0401-2653</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0264410X18316384$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30551987$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Brotherton, Julia ML</creatorcontrib><creatorcontrib>Hawkes, David</creatorcontrib><creatorcontrib>Sultana, Farhana</creatorcontrib><creatorcontrib>Malloy, Michael J.</creatorcontrib><creatorcontrib>Machalek, Dorothy A.</creatorcontrib><creatorcontrib>Smith, Megan A.</creatorcontrib><creatorcontrib>Garland, Suzanne M.</creatorcontrib><creatorcontrib>Saville, Marion</creatorcontrib><title>Age-specific HPV prevalence among 116,052 women in Australia’s renewed cervical screening program: A new tool for monitoring vaccine impact</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>•HPV based cervical screening can generate precise HPV prevalence estimates.•Among 116,118 samples from Australian women aged 25–74, 9.2% had oncogenic HPV.•HPV16/18 was stable with age, unlike other oncogenic types, due to HPV vaccination.
Australia’s transition to primary human papillomavirus (HPV) based cervical screening, has for the first time, provided a passive mechanism for monitoring the impact of vaccination on infection prevalence among women attending screening. We assessed oncogenic HPV prevalence by single year of age in the first 7 months of the program, using data collected from a large screening laboratory in Victoria, Australia, which is routinely screening using cobas 4800, cobas 6800 and Seegene assays. Among 116,052 primary screening samples from women aged 25–74, 9.25% (95%CI: 9.09–9.42%) had oncogenic HPV detected: 2.14% (95%CI: 2.05–2.22%) were 16/18 positive and 7.12% (95%CI: 6.97–7.27%) were positive for only non-16/18 HPV. Prevalence peaked at age 25–29 then decreased with age, but this was driven by non-16/18 types. HPV16/18 prevalence remained low and flat across ages, contrasting with pre-vaccination epidemiology when HPV16/18 peaked in young women. HPV-based screening can precisely monitor HPV prevalence.</description><subject>Age</subject><subject>Australia</subject><subject>Cellular biology</subject><subject>Cervical cancer</subject><subject>Cervical screening</subject><subject>Confidence intervals</subject><subject>Epidemiology</subject><subject>Human papillomavirus</subject><subject>Infections</subject><subject>Laboratories</subject><subject>Medical screening</subject><subject>Monitoring</subject><subject>Pathology</subject><subject>Prevalence</subject><subject>Sexual behavior</subject><subject>Surveillance</subject><subject>Vaccination</subject><subject>Vaccines</subject><subject>Womens health</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkbGO1DAQhi0E4paDRwBZoqEgwRPHcUKDVifgkE6CAhCd5UwmK6-SONjJnuh4AR6A1-NJ8GoXChoqN9__e2Y-xh6DyEFA9WKfHyyimygvBNQ5QC60usM2UGuZFQrqu2wjiqrMShBfLtiDGPdCCCWhuc8upFAKmlpv2I_tjrI4E7reIb_-8JnPgQ52oAmJ29FPOw5QPReq4Ld-pIm7iW_XuAQ7OPvr-8_IA010Sx1HCgeHduARA9HkUnIOfhfs-JJveWL44v3Aex94qnWLD0fkvAR342xxecju9XaI9Oj8XrJPb15_vLrObt6_fXe1vclQNnLJalGJtmw7RN0q0KKlRkJfSVQCSbQIpIsG2qqQWPYdIFIpdV-T7rGBvuvkJXt26k0Tfl0pLmZ0EWkY7ER-jaYApauq1lAm9Ok_6N6vYUrTJaoqtAQpmkSpE4XBxxioN3Nwow3fDAhz9GX25ryqOfoyACb5Srkn5_a1Han7m_ojKAGvTgClcxwcBRPRHeV0LhAupvPuP1_8BmBYqvI</recordid><startdate>20190114</startdate><enddate>20190114</enddate><creator>Brotherton, Julia ML</creator><creator>Hawkes, David</creator><creator>Sultana, Farhana</creator><creator>Malloy, Michael J.</creator><creator>Machalek, Dorothy A.</creator><creator>Smith, Megan A.</creator><creator>Garland, Suzanne M.</creator><creator>Saville, Marion</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0401-2653</orcidid></search><sort><creationdate>20190114</creationdate><title>Age-specific HPV prevalence among 116,052 women in Australia’s renewed cervical screening program: A new tool for monitoring vaccine impact</title><author>Brotherton, Julia ML ; Hawkes, David ; Sultana, Farhana ; Malloy, Michael J. ; Machalek, Dorothy A. ; Smith, Megan A. ; Garland, Suzanne M. ; Saville, Marion</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c393t-8060b4bdcc7b5170be931f63c50ce0bc1e7291b623c4fd1cce437f8e7fc91fdd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Age</topic><topic>Australia</topic><topic>Cellular biology</topic><topic>Cervical cancer</topic><topic>Cervical screening</topic><topic>Confidence intervals</topic><topic>Epidemiology</topic><topic>Human papillomavirus</topic><topic>Infections</topic><topic>Laboratories</topic><topic>Medical screening</topic><topic>Monitoring</topic><topic>Pathology</topic><topic>Prevalence</topic><topic>Sexual behavior</topic><topic>Surveillance</topic><topic>Vaccination</topic><topic>Vaccines</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brotherton, Julia ML</creatorcontrib><creatorcontrib>Hawkes, David</creatorcontrib><creatorcontrib>Sultana, Farhana</creatorcontrib><creatorcontrib>Malloy, Michael J.</creatorcontrib><creatorcontrib>Machalek, Dorothy A.</creatorcontrib><creatorcontrib>Smith, Megan A.</creatorcontrib><creatorcontrib>Garland, Suzanne M.</creatorcontrib><creatorcontrib>Saville, Marion</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied & Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brotherton, Julia ML</au><au>Hawkes, David</au><au>Sultana, Farhana</au><au>Malloy, Michael J.</au><au>Machalek, Dorothy A.</au><au>Smith, Megan A.</au><au>Garland, Suzanne M.</au><au>Saville, Marion</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Age-specific HPV prevalence among 116,052 women in Australia’s renewed cervical screening program: A new tool for monitoring vaccine impact</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2019-01-14</date><risdate>2019</risdate><volume>37</volume><issue>3</issue><spage>412</spage><epage>416</epage><pages>412-416</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>•HPV based cervical screening can generate precise HPV prevalence estimates.•Among 116,118 samples from Australian women aged 25–74, 9.2% had oncogenic HPV.•HPV16/18 was stable with age, unlike other oncogenic types, due to HPV vaccination.
Australia’s transition to primary human papillomavirus (HPV) based cervical screening, has for the first time, provided a passive mechanism for monitoring the impact of vaccination on infection prevalence among women attending screening. We assessed oncogenic HPV prevalence by single year of age in the first 7 months of the program, using data collected from a large screening laboratory in Victoria, Australia, which is routinely screening using cobas 4800, cobas 6800 and Seegene assays. Among 116,052 primary screening samples from women aged 25–74, 9.25% (95%CI: 9.09–9.42%) had oncogenic HPV detected: 2.14% (95%CI: 2.05–2.22%) were 16/18 positive and 7.12% (95%CI: 6.97–7.27%) were positive for only non-16/18 HPV. Prevalence peaked at age 25–29 then decreased with age, but this was driven by non-16/18 types. HPV16/18 prevalence remained low and flat across ages, contrasting with pre-vaccination epidemiology when HPV16/18 peaked in young women. HPV-based screening can precisely monitor HPV prevalence.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>30551987</pmid><doi>10.1016/j.vaccine.2018.11.075</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-0401-2653</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2019-01, Vol.37 (3), p.412-416 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2157668714 |
| source | Elsevier ScienceDirect Journals Complete |
| subjects | Age Australia Cellular biology Cervical cancer Cervical screening Confidence intervals Epidemiology Human papillomavirus Infections Laboratories Medical screening Monitoring Pathology Prevalence Sexual behavior Surveillance Vaccination Vaccines Womens health |
| title | Age-specific HPV prevalence among 116,052 women in Australia’s renewed cervical screening program: A new tool for monitoring vaccine impact |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-20T20%3A52%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Age-specific%20HPV%20prevalence%20among%20116,052%20women%20in%20Australia%E2%80%99s%20renewed%20cervical%20screening%20program:%20A%20new%20tool%20for%20monitoring%20vaccine%20impact&rft.jtitle=Vaccine&rft.au=Brotherton,%20Julia%20ML&rft.date=2019-01-14&rft.volume=37&rft.issue=3&rft.spage=412&rft.epage=416&rft.pages=412-416&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2018.11.075&rft_dat=%3Cproquest_cross%3E2157668714%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2162731309&rft_id=info:pmid/30551987&rft_els_id=S0264410X18316384&rfr_iscdi=true |